Abstract: An object is to provide a dried amniotic membrane that promotes regeneration of a tendon and a tendon sheath when a tendon injury has occurred and that reduces loss of the motor function of fingers of upper limbs and lower limbs due to tendon adhesion as a novel regeneration material.

Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.

Abstract: The present invention relates to sunscreen or daily care compositions comprising butyl methoxydibenzoylmethane, at least one UV filter selected from triazine derivatives, at least one photostabilizer selected from butyl octyl salicylate, benzotriazolyl dodecyl p cresol, ethyl hexyl methoxycrylene, polyester-8, diethyl hexyl syringylidenemalonate, trimethoxybenzylidene pentanedione, diethylhexyl 2,6-naphthalate, a fused ring cyanoacrylate derivative and polyester-25, wherein the composition does not comprise octocrylene and ethyl hexyl methoxy cinnamate.

Abstract: The present invention relates to sunscreen or daily care composition comprising (i) hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate); and (ii) 1-(4-(1,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (INCI butyl methoxydibenzoylmethane); and (iii) 2,4-bis-{[4-(2-ethy-hexyoxy)-2-hydroxy]-pheny}-6-(4-methoxypheny)-1,3,5 triazine (INCI bis-ethylhexyloxyphenol methoxyphenyl triazine); and (iv) 4,4?,4?-(1,3,5-triazine-2,4,6-triyltriimino)tris-benzoic acid-tris(2-ethylhexyl)ester (INCI ethylhexyl triazone) and/or 4, 4?-[[6-[[4-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]amino]-1,3,5-triazin-2,4-diyl]diimino]bis-benzoic acid-bis(2-ethylhexyl)ester (INCI diethyl-hexyl-butamidotriazone); and (v) at least one organic particulate UV filter, wherein the composition is free of ethylhexyl-2-cyano-3, 3-diphenyl-acrylate (INCI octocrylene), 2-ethylhexyl-(2E)-3-(4-methoxyphenyl) acrylate (INCI ethylhexyl methoxy cinnamate) and pp benzylidene malonates, and wherei

Abstract: A novel ROS-responsive prodrug is provided. The prodrug utilizes a unique modified oxalate linker conjugated to 4-aminophenol, which can enhance the reaction kinetics for intracellular ROS within tumor tissues while keeping the modified oxalate backbone stable with amide bond under very low ROS level.

Abstract: Provided is a method for prevention or treatment of a lysosomal storage disorder, and more particularly, to a method that may exhibit excellent efficacy against various lysosomal storage disorders including Niemann-Pick disease by including graphene quantum dots.

Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.

Abstract: There is disclosed a formulation suitable for the reduction or prevention of contamination of articles by microorganisms. The formulation includes at least one block copolymer of ethylene oxide and propylene oxide, at least one polyacrylic acid salt, and at least one propoxylated ethylenediamine compound.

Abstract: Novel compounds able to absorb UV radiation and comprise antimicrobial properties as well. The compounds are novel and undisclosed scytonemin analogs, able to absorb up to 90% of UV-A radiation and can cover a broader UV to blue light absorption range from 293 nm to 500 nm. When mixtures of more than one compound are used, their synergetic absorption properties can cover an even broader spectrum within 293 nm to 500 nm. The compounds present faint coloration, and some are even colorless, therefor the present compounds can be easily incorporated in formulations to be used in cosmetic products, sunscreens or lenses for sunglasses.

Abstract: This disclosure relates to palladium hyaluronic acid particles such as dibenzylideneacetone palladium hyaluronic acid particles. In certain embodiments, this disclosure relates to methods of managing cancer or angiogenic conditions using particles disclosed herein and pharmaceutical compositions comprising the same. In certain embodiments, an objective of this disclosure is hyaluronic acid targeting of CD44, a tumor stem cell marker. In certain embodiments, this disclosure relates to treatment with hyaluronic acid palladium particles disclosed herein for depleting CD44 cells.

Abstract: The present invention relates to a composition comprising melatonin encapsulated within a calcium alginate hydrogel. It further provides an orally administrable dosage form comprising such a composition held within a gel, wherein the gel is formed using starch as a gelling agent. Processes to produce these compositions, as well as their use in therapy, are also disclosed.

Abstract: Technical field The invention relates to new calibrated-size gas-filled microvesicles bearing an overall positive charge, to their use and to their method of manufacturing. The gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.25 or lower and a stabilizing envelope comprising an amphiphilic material, said amphiphilic material comprising a cationic lipid and a neutral or cationic amphiphilic polymeric compound.

Abstract: Embodiments herein relate to active agent depots formed in situ and related methods. In various embodiments, a method of forming an active agent depot in situ is included. The method can include contacting a composition with a vessel wall, wherein the composition includes an active agent and a fibrin promoting vessel wall transfer agent wherein the ratio of active agent to fibrin promoting vessel wall transfer agent (wt./wt.) is at least 5:1. The method also includes transferring the composition from a device surface to the vessel wall surface. The method also includes forming a fibrin matrix around the composition. Other embodiments are also included herein.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: A polymer blend is provided comprising: a single stage polymer and a silicone-grafted vinyl copolymer; wherein the single stage polymer comprises: structural units of a monoethylenically unsaturated non-ionic monomer; structural units of a monoethylenically unsaturated carboxylic acid monomer; and structural units of a multiethylenically unsaturated monomer having at least two ethylenically unsaturated groups per molecule; and wherein the silicone-grafted vinyl copolymer, comprises: structural units of a vinyl monomer; and structural units of a carbosiloxane dendrimer of formula (I). Also provided is a suncare formulation comprising the polymer blend in a dermatologically acceptable carrier with a suncare active.

Abstract: The present invention relates to thermostable quick-dissolving thin films comprising a biological moiety and an excipient mix which are suitable for the formulation of biological moieties such as viral vaccines, to methods for manufacturing such thermostable quick-dissolving thin films, and to their use in therapy. The excipient mix comprises one or more water-soluble polymer(s), a sugar selected from sucrose, trehalose and a combination thereof, a metal ion, a carboxylate, and a buffering agent.

Abstract: According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

Abstract: The invention describes a buffered oral aqueous apixaban suspension comprising 0.08-0.20 w/v % micronized apixaban having a pH of 1.5-6.5 and a method for the preparation thereof.

Abstract: An object of the present disclosure is providing a hard capsule made of a hard capsule film having enteric properties that can be molded by a cold gel method. An enteric hard capsule comprises a film containing a first component and a second component, and further containing at least one component selected from the group consisting of a third component, a fourth component, and a fifth component, wherein the first component is a nonionic water-soluble cellulose compound having a viscosity value within a range of from 100 mPa·s to 100,000 mPa·s, the second component is an enteric methacrylic acid copolymer, the third component is an enteric cellulose compound, wherein the fourth component is a water-insoluble (meth)acrylic acid alkyl ester copolymer, and the fifth component is at least one kind selected from the group consisting of polyvinyl alcohol, a plasticizer, and a surfactant.